NCT00453193View on ClinicalTrials.gov

Alemtuzumab and Pentostatin In T-cell Neoplasms

PHASE2TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
LymphomaLeukemia
Interventions
DRUG

Pentostatin

4 mg/m\^2 IV weekly for 4 weeks then every 2 weeks

DRUG

Alemtuzumab

30 mg IV three times weekly

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

collaborator

Bayer

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER